Compare IRON & UPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRON | UPST |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2020 | 2020 |
| Metric | IRON | UPST |
|---|---|---|
| Price | $69.83 | $32.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $103.18 | $45.84 |
| AVG Volume (30 Days) | 384.6K | ★ 4.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 131.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,043,857,000.00 |
| Revenue This Year | N/A | $34.45 |
| Revenue Next Year | $283.52 | $32.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 63.99 |
| 52 Week Low | $40.00 | $23.97 |
| 52 Week High | $99.50 | $85.31 |
| Indicator | IRON | UPST |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 55.60 |
| Support Level | $64.48 | $25.18 |
| Resistance Level | $71.85 | $35.24 |
| Average True Range (ATR) | 3.26 | 2.11 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 64.61 | 61.80 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).